Patients were stratified by stage ( IIIA vs IIIB ) , response to chemoradiotherapy ( stable disease vs objective response ) , delivery of chemoradiotherapy ( concurrent vs sequential ) , and region using block randomisation , and were randomly assigned ( 2:1 , double-blind ) by a central interactive voice randomisation system to either tecemotide or placebo .